You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, April 2014
|
| DOI | 10.1186/1750-1172-9-48 |
| Pubmed ID | |
| Authors |
Tetsuya Tanimoto, Eiji Kusumi, Kazutaka Hosoda, Kaduki Kouno, Tamae Hamaki, Masahiro Kami |
| Abstract |
An orphan medicinal product, eculizumab is approved in Japan and globally for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab therapy can cause late complement pathway deficiencies that predispose patients to meningococcal infections. Although meningococcal vaccinations are typically considered mandatory for eculizumab therapy, no approved vaccine is available in Japan as of March, 2014. Advertising unapproved, privately imported pharmaceuticals is prohibited under Japanese pharmaceutical law; detailed information concerning the unapproved meningococcal vaccines is therefore not widely available. The situation jeopardizes the safety of patients receiving eculizumab therapy, and Japanese clinicians are advised caution when prescribing this therapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 4% |
| United States | 1 | 4% |
| Unknown | 22 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 6 | 25% |
| Student > Master | 6 | 25% |
| Other | 5 | 21% |
| Professor | 2 | 8% |
| Librarian | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 1 | 4% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 17% |
| Psychology | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Economics, Econometrics and Finance | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 1 | 4% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2014.
All research outputs
#19,945,185
of 25,374,917 outputs
Outputs from Orphanet Journal of Rare Diseases
#2,289
of 3,105 outputs
Outputs of similar age
#168,926
of 241,397 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#41
of 46 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,397 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.